OncoImmune raises $15M for PhII GvHD study; FDA wraps biosimilar naming guidance
• Rockville, MD-based OncoImmune has raised a $15 million Series A round. 3E Bioventures Capital led the round, which is primarily focused on a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
